title: Outcomes for COPD pharmacological trials: from lung function to biomarkers.
abstract: The American Thoracic Society/European Respiratory Society jointly created a Task Force on "Outcomes for COPD pharmacological trials: from lung function to biomarkers" to inform the chronic obstructive pulmonary disease research community about the possible use and limitations of current outcomes and markers when evaluating the impact of a pharmacological therapy. Based on their review of the published literature, the following document has been prepared with individual sections that address specific outcomes and markers, and a final section that summarises their recommendations.
authors.affiliation: Unit of Respiratory Diseases, Dept of Internal Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy. mario.cazzola@uniroma2.it
authors.forename: M
authors.initials: M
authors.lastname: Cazzola
authors.forename: W
authors.initials: W
authors.lastname: MacNee
authors.forename: F J
authors.initials: FJ
authors.lastname: Martinez
authors.forename: K F
authors.initials: KF
authors.lastname: Rabe
authors.forename: L G
authors.initials: LG
authors.lastname: Franciosi
authors.forename: P J
authors.initials: PJ
authors.lastname: Barnes
authors.forename: V
authors.initials: V
authors.lastname: Brusasco
authors.forename: P S
authors.initials: PS
authors.lastname: Burge
authors.forename: P M A
authors.initials: PM
authors.lastname: Calverley
authors.forename: B R
authors.initials: BR
authors.lastname: Celli
authors.forename: P W
authors.initials: PW
authors.lastname: Jones
authors.forename: D A
authors.initials: DA
authors.lastname: Mahler
authors.forename: B
authors.initials: B
authors.lastname: Make
authors.forename: M
authors.initials: M
authors.lastname: Miravitlles
authors.forename: C P
authors.initials: CP
authors.lastname: Page
authors.forename: P
authors.initials: P
authors.lastname: Palange
authors.forename: D
authors.initials: D
authors.lastname: Parr
authors.forename: M
authors.initials: M
authors.lastname: Pistolesi
authors.forename: S I
authors.initials: SI
authors.lastname: Rennard
authors.forename: M P
authors.initials: MP
authors.lastname: Rutten-van Mölken
authors.forename: R
authors.initials: R
authors.lastname: Stockley
authors.forename: S D
authors.initials: SD
authors.lastname: Sullivan
authors.forename: J A
authors.initials: JA
authors.lastname: Wedzicha
authors.forename: E F
authors.initials: EF
authors.lastname: Wouters
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D026683:Advisory Committees; D015415:Biomarkers / Q000097:blood*; D001993:Bronchodilator Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D017410:Practice Guidelines as Topic; D011379:Prognosis; D029424:Pulmonary Disease, Chronic Obstructive / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality*; D012129:Respiratory Function Tests; D018570:Risk Assessment; D012955:Societies, Medical; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000305:Adrenal Cortex Hormones; D015415:Biomarkers; D001993:Bronchodilator Agents